Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDX Celldex Therapeutics

Post-Mkt 07-13 19:16:53 EDT

38.53

-0.58

-1.48%

盘后38.53

+0.000.00%

18:18 EDT

High38.66	Low37.53	Vol660.19K
Open38.61	D1 Closing39.11	Amplitude2.90%
Mkt Cap3.02B	Tradable Cap2.79B	Total Shares78.49M
T/O25.30M	T/O Rate0.91%	Tradable Shares72.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDX","market":"US","secType":"STK","nameCN":"Celldex Therapeutics","latestPrice":38.53,"timestamp":1783972800000,"preClose":39.11,"halted":0,"volume":660189,"hourTrading":{"tag":"盘后","latestPrice":38.53,"preClose":38.53,"latestTime":"18:18 EDT","volume":92765,"amount":3574241.94355,"timestamp":1783981120719,"change":0,"changeRate":0,"amplitude":0.031404},"delay":0,"changeRate":-0.014829966760419287,"floatShares":72463400,"shares":78492100,"eps":-4.267422,"marketStatus":"Post-Mkt","change":-0.58,"latestTime":"07-13 19:16:53 EDT","open":38.61,"high":38.66,"low":37.525,"amount":25298191.60818,"amplitude":0.029021,"askPrice":39.28,"askSize":35,"bidPrice":37.79,"bidSize":52,"shortable":3,"etf":0,"ttmEps":-4.267422,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1783987200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":515304000000,"exchange":"NASDAQ","adjPreClose":39.11,"preHourTrading":{"tag":"盘前","latestPrice":38.6737,"preClose":39.11,"latestTime":"09:15 EDT","volume":181,"amount":7061.640246999999,"timestamp":1783948525937,"change":-0.4363,"changeRate":-0.011156,"amplitude":0.076451},"postHourTrading":{"tag":"盘后","latestPrice":38.53,"preClose":38.53,"latestTime":"18:18 EDT","volume":92765,"amount":3574241.94355,"timestamp":1783981120719,"change":0,"changeRate":0,"amplitude":0.031404},"volumeRatio":0.6477,"impliedVol":0.621,"impliedVolPercentile":0.7131},"requestUrl":"/m/hq/s/CLDX/tweets","defaultTab":"tweets","newsList":[{"id":"2649147096","title":"Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649147096","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649147096?lang=en_us&edition=fundamental","pubTime":"2026-07-06 08:31","pubTimestamp":1783297888,"startTime":"0","endTime":"0","summary":"In late June 2026, Celldex Therapeutics, Inc. was added to multiple Russell growth benchmarks, including the Russell 2000 Growth, 2500 Growth, 3000 Growth, 3000E Growth and Russell Small Cap Comp Growth indexes. \nThis broad inclusion meaningfully increases Celldex’s visibility to institutional investors and index-tracking funds, potentially deepening liquidity and broadening its shareholder base.\nNext, we’ll examine how Celldex’s broad Russell growth index inclusion shapes its investment...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-is-up-88-after-broad-russell-growt","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-is-up-88-after-broad-russell-growt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648475415","title":"Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2648475415","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648475415?lang=en_us&edition=fundamental","pubTime":"2026-07-02 00:00","pubTimestamp":1782921617,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) has just been added to several Russell growth benchmarks, coinciding with updated long term Phase 2 data for barzolvolimab in angioedema, a combination that is drawing fresh attention to the stock.\nSee our latest analysis for Celldex Therapeutics.\nThe latest Russell index additions and the updated barzolvolimab data come after a strong period for Celldex Therapeutics, with a year to date share price return of 37.76% and a 1 year total shareholder return of 75.44%,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-enters-russell-growth-indexes-as-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-enters-russell-growth-indexes-as-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DCF","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646335747","title":"Celldex Therapeutics Shareholders Approve 3,400,000-share Increase to 2021 Equity Plan at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2646335747","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646335747?lang=en_us&edition=fundamental","pubTime":"2026-06-26 20:47","pubTimestamp":1782478032,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics shareholders approve 3,400,000-share increase to 2021 equity plan at annual meetingCelldex held its annual shareholder meeting on June 25, 2026.Shareholders ratified Pricewaterhou","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL7XX409:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644106065","title":"Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2644106065","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644106065?lang=en_us&edition=fundamental","pubTime":"2026-06-20 02:46","pubTimestamp":1781894794,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) is back in focus after presenting long term barzolvolimab data in chronic spontaneous urticaria and early CDX-622 results at a major allergy congress, spotlighting its mast cell targeted pipeline.\nSee our latest analysis for Celldex Therapeutics.\nCelldex Therapeutics shares trade at US$32.43, with a year to date share price return of 20.07% and a 1 year total shareholder return of 58.20%. This suggests recent barzolvolimab and CDX-622 data are contributing to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-stock-could-be-61-below-fair-value","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-stock-could-be-61-below-fair-value","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DCF","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644054015","title":"QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2644054015","media":"InvestorPlace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644054015?lang=en_us&edition=fundamental","pubTime":"2026-06-19 20:24","pubTimestamp":1781871896,"startTime":"0","endTime":"0","summary":"https://www.youtube.com/live/nFu_fTQv1_Q Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open.  UniQure NV…","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"investorplace_stock_picks","url":"https://investorplace.com/dailylive/2026/06/qure-was-just-the-beginning-5-biotech-catalysts-to-watch/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://investorplace.com/dailylive/2026/06/qure-was-just-the-beginning-5-biotech-catalysts-to-watch/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["LU0889565916.HKD","QURE","LABU","XBI","CLDX","IONS","REPL","CELC","LU0109394709.USD","BK4139","LU0320765992.SGD","TVTX","BK4585","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644454727","title":"Why Celldex Therapeutics (CLDX) Is Up 12.2% After CSU Drug Data Suggest Disease Modification Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2644454727","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644454727?lang=en_us&edition=fundamental","pubTime":"2026-06-18 05:30","pubTimestamp":1781731817,"startTime":"0","endTime":"0","summary":"In June 2026, Celldex Therapeutics reported long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria and Phase 1 data for CDX-622, showing rapid, durable angioedema improvement and mast cell depletion, respectively, presented at the European Academy of Allergy and Clinical Immunology meeting in Istanbul.\nThe finding that up to 64% of barzolvolimab-treated patients with baseline angioedema remained angioedema-free seven months after dosing raises the prospect of shifting...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/why-celldex-therapeutics-cldx-is-up-122-after-csu-drug-data","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/why-celldex-therapeutics-cldx-is-up-122-after-csu-drug-data","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643420167","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2643420167","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643420167?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:01","pubTimestamp":1781532105,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celldex (CLDX), Teva Pharmaceutical (TEVA) and Eli L...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-224?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-224?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4557","BK4139","BK4566","BK4559","LU1983299246.USD","BK4596","BK4584","LU2324357040.USD","BK4585","CLDX","BK4588","TEVA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643277306","title":"Celldex Therapeutics Price Target Maintained With a $42.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2643277306","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643277306?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:30","pubTimestamp":1781519400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 15, 2026 06:30 ET (10:30 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643247781","title":"Celldex presents long-term results from Phase 2 study of barzolvolimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2643247781","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643247781?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:55","pubTimestamp":1781470530,"startTime":"0","endTime":"0","summary":"Celldex (CLDX) announced the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Acad...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-presents-long-term-results-from-phase-2-study-of-barzolvolimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-presents-long-term-results-from-phase-2-study-of-barzolvolimab-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPV","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643247739","title":"Celldex presents first-in-human results for CDX-622","url":"https://stock-news.laohu8.com/highlight/detail?id=2643247739","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643247739?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:50","pubTimestamp":1781470228,"startTime":"0","endTime":"0","summary":"Celldex (CLDX) presented positive results from the Phase 1 healthy participant study of CDX-622 at the European Academy of Allergy and Clinical Imm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-presents-first-in-human-results-for-cdx-622-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-presents-first-in-human-results-for-cdx-622-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPV","CLDX","CDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643244311","title":"Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643244311","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643244311?lang=en_us&edition=fundamental","pubTime":"2026-06-14 22:36","pubTimestamp":1781447768,"startTime":"0","endTime":"0","summary":"June 14 (Reuters) - Celldex Therapeutics Inc ::*CELLDEX PRESENTS LONG-TERM BARZOLVOLIMAB RESULTS DEMONSTRATING SUSTAINED OFF-TREATMENT IMPROVEMENT IN ANGIOEDEMA IN PATIENTS WITH CSU AT THE EUROPEAN AC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nRSDbmdsqy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643244892","title":"Celldex says Phase 2 barzolvolimab data show sustained off-treatment angioedema improvement in CSU patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2643244892","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643244892?lang=en_us&edition=fundamental","pubTime":"2026-06-14 22:21","pubTimestamp":1781446874,"startTime":"0","endTime":"0","summary":"Celldex presented long-term Phase 2 results for barzolvolimab at the EAACI annual meeting, highlighting sustained off-treatment improvement in CSU-related angioedema.Patients showed rapid relief during treatment, with benefits persisting months after dosing ended, supporting a potential shift beyond symptom control.Two Phase 3 CSU trials are fully enrolled, with topline results expected in Q4 2026, positioning the program for a planned 2027 BLA filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nNDLb9mWmZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","CLDX","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","BK4139","BK4112","NDAQ","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4585","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643895244","title":"Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained off-Treatment Improvement in Angioedema in Patients With Csu at the European Academy of Allergy and Clinical Immunology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643895244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643895244?lang=en_us&edition=fundamental","pubTime":"2026-06-14 22:21","pubTimestamp":1781446860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nTUA60T4GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643448112","title":"Celldex Therapeutics - Barzolvolimab Meets Primary Efficacy Endpoint in Phase 2 Csu Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643448112","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643448112?lang=en_us&edition=fundamental","pubTime":"2026-06-14 22:21","pubTimestamp":1781446860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nTUA60T4GM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643462972","title":"Celldex reports positive Phase 1 results for bispecific antibody CDX-622 in healthy participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2643462972","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643462972?lang=en_us&edition=fundamental","pubTime":"2026-06-14 17:15","pubTimestamp":1781428517,"startTime":"0","endTime":"0","summary":"Celldex presented first-in-human Phase 1 results for bispecific antibody CDX-622 at the EAACI Annual Meeting.Findings showed clear evidence of mast cell suppression consistent with the drug’s intended mechanism, supporting further development in inflammatory diseases.The study reported a favorable tolerability profile across tested doses, with no major safety signals flagged.CDX-622 is in a Phase 1b proof-of-mechanism study in mild to moderate asthma, with additional proof-of-concept studies planned in allergic rhinitis, food allergy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nNDL35PC3S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4139","IE00BKPKM429.USD","IE00B64PRP62.GBP","NDAQ","LU2095319765.USD","CLDX","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4585","SG9999014039.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BK4588","LU0314104364.USD","BK4112","IE00BN0W2W23.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643246292","title":"Celldex Presents Positive First-in-Human Results From Phase 1 Study of Novel Bispecific Cdx-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2643246292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643246292?lang=en_us&edition=fundamental","pubTime":"2026-06-14 17:15","pubTimestamp":1781428500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nTUA7LCVPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642447563","title":"Celldex to present barzolvolimab, CDX-622 data at EAACI annual congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2642447563","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642447563?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:01","pubTimestamp":1781121687,"startTime":"0","endTime":"0","summary":"Celldex will present barzolvolimab and CDX-622 data at the EAACI Annual Congress in Istanbul, June 12-15, 2026.Barzolvolimab flash talks are scheduled for June 14, covering CSU angioedema outcomes and a ColdU patient-reported itch scale validation.A late-breaking poster on Phase 1 CDX-622 healthy-volunteer results is set for June 14, highlighting bispecific targeting of SCF and TSLP.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL1BLCkY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","CLDX","NDAQ","LU2210149790.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642606475","title":"Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2642606475","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642606475?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:01","pubTimestamp":1781121660,"startTime":"0","endTime":"0","summary":"-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June  10, 2026  (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3310079/24180/en/Celldex-Announces-Multiple-Upcoming-Presentations-from-Leading-Mast-Cell-Targeting-Pipeline-at-the-Upcoming-2026-European-Academy-of-Allergy-and-Clinical-Immunology-Annual-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLI","TSLG","BK4213","TSLW","09366","TLA","TSLP","PRO","CRSH","SD","TSII","TSDD","EPV","TSYY","BK4132","TESL","TSLQ","PN","09766","TEST","TSLO","07366","BK4139","BK4023","TSLR","TSLZ","AD","TSLL","TSLT","TSLS","BK4096","TSLY","07766","TSL","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642647864","title":"Celldex Therapeutics Is Maintained at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2642647864","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642647864?lang=en_us&edition=fundamental","pubTime":"2026-06-11 01:34","pubTimestamp":1781112840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 10, 2026 13:34 ET (17:34 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642421254","title":"UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2642421254","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642421254?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:59","pubTimestamp":1781099944,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) has an average rating of buy and mean price target of $57.53, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celldex.com","stockEarnings":[{"period":"1week","weight":0.0193},{"period":"1month","weight":0.3325},{"period":"3month","weight":0.2131},{"period":"6month","weight":0.4284},{"period":"1year","weight":0.7244},{"period":"ytd","weight":0.44}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.55,"avgChangeRate":0.123409},{"month":2,"riseRate":0.425,"avgChangeRate":-0.00139},{"month":3,"riseRate":0.475,"avgChangeRate":0.004594},{"month":4,"riseRate":0.5,"avgChangeRate":0.003159},{"month":5,"riseRate":0.275,"avgChangeRate":-0.021672},{"month":6,"riseRate":0.512195,"avgChangeRate":0.146914},{"month":7,"riseRate":0.439024,"avgChangeRate":-0.011437},{"month":8,"riseRate":0.375,"avgChangeRate":-0.027935},{"month":9,"riseRate":0.325,"avgChangeRate":-0.018185},{"month":10,"riseRate":0.5,"avgChangeRate":0.004664},{"month":11,"riseRate":0.575,"avgChangeRate":0.057317},{"month":12,"riseRate":0.45,"avgChangeRate":-0.008619}],"exchange":"NASDAQ","name":"Celldex Therapeutics","nameEN":"Celldex Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Celldex Therapeutics,CLDX,Celldex Therapeutics股票,Celldex Therapeutics股票老虎,Celldex Therapeutics股票老虎国际,Celldex Therapeutics行情,Celldex Therapeutics股票行情,Celldex Therapeutics股价,Celldex Therapeutics股市,Celldex Therapeutics股票价格,Celldex Therapeutics股票交易,Celldex Therapeutics股票购买,Celldex Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}